SRY Inhibitors
The SRY (Sex-determining Region Y) protein is a transcription factor encoded by the SRY gene located on the Y chromosome. It plays a pivotal role in male sex determination during embryonic development in mammals. SRY is expressed in the bipotential gonadal ridge of the early embryo and functions to initiate the differentiation of the gonadal primordium into testes, thus triggering the male developmental pathway. The SRY protein accomplishes this by binding to specific DNA sequences known as SRY boxes within the regulatory regions of target genes involved in testis development, such as Sox9. Through its transcriptional regulatory activity, SRY facilitates the upregulation of key genes involved in testicular differentiation while suppressing the expression of genes associated with ovarian development, thereby orchestrating the intricate process of sex determination.
Inhibition of SRY activity can be achieved through various mechanisms, primarily focusing on disrupting its DNA-binding ability or interfering with its protein-protein interactions essential for transcriptional regulation. Small molecules or peptides that target the DNA-binding domain of SRY can competitively inhibit its binding to target gene promoters, thereby preventing the initiation of transcriptional programs required for testis development. Alternatively, molecules that disrupt protein-protein interactions involving SRY, such as those with its co-factors or binding partners, can interfere with its transcriptional regulatory function. Additionally, post-translational modifications or regulatory proteins may modulate SRY activity by altering its stability, subcellular localization, or DNA-binding affinity, providing additional avenues for inhibition. Understanding the mechanisms underlying SRY inhibition offers insights into potential strategies for modulating sex determination processes and elucidating the molecular basis of disorders of sexual development.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K). It acts by binding to the ATP-binding site of the enzyme, thus preventing the phosphorylation of inositol lipids and the subsequent activation of Akt. As Akt is a key regulator of Androgen Receptor (AR) transactivation, the inhibition of Akt by LY294002 can indirectly affect the SRY-related function of AR. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that binds to FKBP12 to inhibit the mTORC1 complex. mTORC1 is involved in protein synthesis, and its inhibition can negatively affect the translation of SRY and therefore its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which prevents the activation of ERK. By inhibiting ERK, PD98059 can indirectly influence SRY by reducing phosphorylation and activation of AR. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. It inhibits this kinase by binding to its ATP pocket, which prevents the phosphorylation of ATF2. Since ATF2 can enhance SRY activity, inhibition of this pathway can indirectly affect SRY function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which acts by competitively binding to the ATP-binding site of JNK, thus inhibiting its kinase activity. As JNK can phosphorylate and activate AR, inhibition of this pathway can indirectly affect SRY function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). By inhibiting ROCK, Y27632 can affect actin cytoskeleton reorganization, which is necessary for AR nuclear translocation. Inhibition of this process can indirectly affect SRY function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. It inhibits PI3K by covalently binding to its ATP-binding site, thus preventing the activation of Akt and consequently reducing AR transactivation. This can indirectly affect SRY function. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII). CaMKII is involved in the phosphorylation and activation of AR. Inhibition of this pathway can indirectly affect SRY function. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö6983 is a broad-spectrum protein kinase C (PKC) inhibitor. PKC is involved in the phosphorylation and activation of AR. By inhibiting this pathway, Gö6983 can indirectly affect SRY function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
GF109203X is a potent inhibitor of PKC. It inhibits PKC by binding to the ATP-binding site of the enzyme, thus preventing the phosphorylation and activation of AR. This can indirectly affect SRY function. | ||||||